EMERYVILLE, Calif.--(BUSINESS WIRE)--KineMed Inc. (www.kinemed.com) today announced the renewal of a non-exclusive research collaboration with Pfizer Inc. (NYSE: PFE) for the advancement of novel approaches in metabolic disease, in particular Type II diabetes. The collaboration employs KineMed’s novel dynamic proteomics technology platform to map the impact of potential drug candidates on specific metabolic pathways.
“We are very pleased to announce the extension of this ongoing partnership in an important area of medicine that affects so many Americans. Our translational biomarker platform targets the metabolic processes and pathways that play a pathogenic role in disorders such as diabetes,” said Marc Hellerstein, M.D., Ph.D., President, Chief Science Officer and Co-founder at KineMed. “This platform has been useful in accelerating advancement and de-risking compounds in Type II diabetes. We look forward to continuing our work with Pfizer on their compounds in preclinical and clinical trials.”
About KineMed, Inc.
KineMed is a growing health technology company that has developed a proprietary biomarker platform technology with broad applications in drug development and medical diagnostics.
Using its patented technology, KineMed has developed analytic biomarker tests which measure, in a single sample, the rate of change of critical biological pathways. KineMed believes that its unique ability to measure the production and destruction of the key molecules involved in disease-modifying biological processes provides meaningful, and previously unavailable, information about both diseases and wellness, which can transform healthcare decisions. KineMed is expanding from its legacy of collaborative pharmaceutical relationships to also establish its own pipeline of therapeutic candidates and diagnostic tests.
For more information about KineMed, please visit: www.kinemed.com